Madrigal builds on liver disease awareness campaigns as it awaits FDA decision on NASH drug resmetirom
Madrigal Pharmaceuticals wants people with fatty liver disease to be the number one fan of their livers. Its new “patient service announcement,” shown first on Thursday in Boston before the annual Liver Meeting, follows one such “fan” as she goes about her day in the neighborhood.
The new video project adds to Madrigal’s ongoing liver disease awareness work around nonalcoholic steatohepatitis, or NASH. Its “Taking on Fatty Liver and NASH” campaign debuted in the summer, while its healthcare professional campaign “NASH Explored” began last year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.